Abstract
Vemurafenib is a potent selective BRAF V600 inhibitor, which demonstrates high effectiveness in the treatment of metastatic BRAF V600 positive melanomas. Vemurafenib generates frequent response rates, prolonging both progression-free survival (PFS) and overall survival (OS).
In some patients, secondary resistance to vemurafenib can occur during the first 6-12 months of the treatment, which may be postponed by a combination of BRAF and MEK inhibitors. Some patients also benefit from monotherapy and survive for 24 months or longer without progression.